Human Microbiome Therapeutics Market Trends 2020 Demand, Industry Size, Share, Growth Status, Top Manufacturers Analysis, CAGR Status, Future Scope and Forecast to 2027

Human Microbiome Therapeutics Market

According to a recent estimate by Emergen Research, the market for human microbiome therapeutics will be valued USD 1,098.4 million by 2027. The growing emphasis on the creation of human microbiome therapies is a major factor in market growth. It is now a recognized target for the creation of new medicines. During the projection period, a variety of growth opportunities for market participants are anticipated to be presented by the increasing number of collaborations between market players. However, it is anticipated that the human microbiome industry would not expand due to a lack of knowledge and insufficient research.

The market for microbiome therapies was severely harmed by the COVID-19 epidemic. Globally, clinical trial research has been significantly interrupted. This is particularly relevant given that weaker populations, who are more at risk of COVID-19 exposure, are commonly included in clinical trials. Seres Therapeutics’ SER-287 development activities was negatively impacted by the COVID-19 epidemic and the stoppage of non-essential medical procedures, such as endoscopies, at multiple clinical sites.

The development of microbiome research is anticipated to contribute in the hunt for more effective cures for infections and other ailments, improving the results of medical therapy. Companies are bringing down the cost of their goods, increasing access to cutting-edge healthcare for a greater percentage of the population, and some countries’ governing authorities are changing their strategies to support the adoption of microbiome-based treatments. As a result, this offers market vendors lucrative growth opportunities to increase their market share.

Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]): Click Here

Some Key Highlights from the Report

BiomX Ltd. stated in August 2019 that a brand-new, cutting-edge production facility had been completed. The new facility, which is headquartered in Ness Ziona, will help BiomX with the clinical development of potential phage products, and it might be expanded in the future to meet demand for commercial manufacturing. In this current phase of live biotherapeutics, which includes phages as well as bacteria and cells produced from humans, the development has been a key step on the path to clinical development.

Probiotics is anticipated to rule the market during the period of forecast. Probiotics are living things, including bacteria and yeasts, that have positive effects on health when taken.

Due to its widespread use, the small molecule therapeutics market category held the greatest market share and was projected to increase at the highest rate during the forecast period.

The infectious illness segment is anticipated to dominate the market during the period of forecast. The widespread use of antibiotics and the rising prevalence of diseases caused by microbial dysbiosis, along with the development of microbiome-based drugs, are the primary drivers of potential growth in the market.

The North American market is anticipated to dominate the global market for Human Microbiome Therapeutics therapeutics due to the rise in dietary supplement consumption.

Oxidien Pharmaceuticals, LLC, BiomX Ltd., LNC Therapeutics SA, Commense Inc., Embion Technologies SA, DermBiont, Inc., CoreBiome, Inc., Carbiotix AB, Biotagenics Inc., and Finch Therapeutics are a few of the important participants.

Emergen Research has segmented the global Human Microbiome Therapeutics Market on the basis of product, approach, therapeutic area, diseases, and region:

Product Outlook (Revenue, USD Million; 2017-2027)

  • Prescription Drugs
  • Probiotics
  • Medical Foods
  • Prebiotics

Approach Outlook (Revenue, USD Million; 2017-2027)

  • Microbial Consortia
  • Phage Cocktail
  • Small Molecule Therapies
  • Microbial Ecosystems
  • Genetically Modified Single Strain Bacteria
  • Single Strain Whole Bacteria

Therapeutic Areas Outlook (Revenue, USD Million; 2017-2027)

  • Oncology
  • Autoimmune Disorders
  • Dermatological Disorders
  • Metabolic Disorders
  • Infectious Disease
  • Others

Diseases Outlook (Revenue, USD Million; 2017-2027)

  • Crohn’s Disease
  • difficile
  • Diabetes
  • Irritable Bowel Syndrome
  • Others

Regional Outlook (Revenue, USD Million; 2017-2027)

  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. UK
    3. France
    4. BENELUX
    5. Rest of Europe
  • Asia Pacific
    1. China
    2. Japan
    3. South Korea
    4. India
    5. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • MEA
    1. Saudi Arabia
    2. UAE
    3. Rest of MEA

Browse Full Report Description + Research Methodology + Table of Content + Infographics @

About Us:

At Emergen Research, we believe in advancing with technology. We are growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Facebook | LinkedIn | Twitter | Blogs

Latest Reports: FMS Like Tyrosine kinase 3 Inhibitors Market, Space In Orbit Refueling Market

Trending Reports: Prepreg Market, Postpartum Depression Market

You may also like...

Leave a Reply

Your email address will not be published.